GlobeNewsWire
25 Aug 2026, 22:33 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Regeneron's Phase 3 clinical trial of Fianlimab in combination with Libtayo for melanoma failed to reach statistical significance for its primary endpoint of progression-free survival. — The failure of a 'potential blockbuster' drug candidate leads to direct loss of projected future revenue and an immediate $11 billion market cap wipeout.
-0.90A securities class action lawsuit has been filed alleging Regeneron misled investors by hiding flawed statistical assumptions and trial struggles between August 2025 and May 2026. — Legal proceedings create ongoing financial liability, management distraction, and reputational damage beyond the initial clinical failure.
-0.40Regeneron admitted to altering the Trial protocol months before notifying investors, citing 'slow event rates' as the reason for the change. — This suggests a lack of transparency in corporate governance and increases the likelihood that the securities fraud litigation will be successful.
-0.30Continue reading
6 related stories
Search tags
Which stocks this story touches
The company is facing a securities fraud class action lawsuit following the failure of a Phase 3 clinical trial and a significant loss in market capitalization.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
